CLAIMS

1. A crystalline form of the compound 2-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol adipic acid salt, wherein the crystalline form is characterized by the presence of peaks in the X-ray powder diffractogram at the following angles of refraction 2θ: 6.9°, 17.8° and 19.2°.

2. A crystalline form of the compound 2-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol adipic acid salt according to claim 1, wherein the crystalline form is characterized by the presence of peaks in the X-ray powder diffractogram at the following angles of refraction 2θ: 6.9°, 12.2°, 16.8°, 17.8° and 19.2°.

3. A crystalline form of the compound 2-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol adipic acid salt according to claim 1, wherein the crystalline form is characterized by the presence of peaks in the X-ray powder diffractogram at the following angles of refraction 2θ: 6.9°, 12.2°, 15.6°, 16.4°, 16.8°, 17.8°, 19.2°, 20.3°, 21.5°, and 22.6°.

4. A crystalline form of the compound 2-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol adipic acid salt according to any one of claims 1 to 3, wherein the crystalline form essentially shows the X-ray powder diffraction pattern as depicted in Figure 1.

5. A crystalline form of the compound 2-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol adipic acid salt according to any one of claims 1 to 4, wherein the crystalline form is characterized by the presence of an endothermic peak in the differential scanning calorimetry thermogram at 163.5±5°C.

6. A process for manufacturing of the crystalline form of the compound 2-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol adipic acid salt according to any one of claims 1 to 5, said process comprising the following steps:

a) providing a first solution/suspension of about 1 eq. adipic acid in acetone;
b) providing a second solution comprising about 1 eq. of the compound 2-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol in acetone;
c) mixing of the first solution/suspension and the second solution, under heating;
d) cooling the resulting mixture;
e) optionally stirring the resulting mixture;
f) isolating the solid residue through a solid-liquid separation; and
g) drying the solid residue.

7. A process for manufacturing according to claim 6, wherein the mixing of the first solution/suspension and the second solution is performed by adding the second solution to the first solution/suspension, under heating.

8. A pharmaceutical composition comprising the crystalline form according to any one of claims 1 to 5, and at least one pharmaceutically acceptable carrier material.

9. The crystalline form according to any one of claims 1 to 5, for use as a medicament.

10. Use of the crystalline form according to any one of claims 1 to 5, in the manufacture of a medicament for the prevention or treatment of an inflammatory/autoimmune disease or disorder.

11. Use of the crystalline form according to any one of claims 1 to 5, in the manufacture of a medicament for the prevention or treatment of an inflammatory/autoimmune disease or disorder selected from a group consisting of hidradenitis suppurativa; ankylosing spondylitis; and primary sclerosing cholangitis.

12. Use of the crystalline form according to any one of claims 1 to 5, in the manufacture of a medicament for the prevention or treatment of a disease or disorder selected from a group consisting of psoriasis.

13. Use of the crystalline form according to any one of claims 1 to 5, in the manufacture of a medicament for the prevention or treatment of cancer, wherein the crystalline form is to be used as a single therapeutic agent or in combination with one or more chemotherapy agents and/or radiotherapy and/or targeted therapy.

14. Use of the crystalline form according to any one of claims 1 to 5, in the manufacture of a medicament for the prevention or treatment of cancer, wherein the crystalline form is to be used as a single therapeutic agent or in combination with one or more chemotherapy agents and/or radiotherapy and/or targeted therapy; wherein said cancer is selected from a group consisting of lymphoma; brain cancer; breast cancer; colorectal cancer; hepatocarcinomas; renal cell carcinoma; lung cancer; and gastric cancer.